Phase 1/2a Study of ANPD001 in Parkinson Disease

PHASE1Enrolling by invitationINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

January 23, 2024

Primary Completion Date

October 30, 2025

Study Completion Date

April 30, 2030

Conditions
Parkinson Disease
Interventions
BIOLOGICAL

ANPD001

Biologic: ANPD001 is an experimental product derived from the patient's own skin cells converted to induced pluripotent stem cells. The stem cells were differentiated into precursors for brain cells that produce dopamine.

DEVICE

Custom Device

A custom device to facilitate slow injection of small volumes of investigational drugs (including cell therapies), under MRI guidance

Trial Locations (9)

11030

Feinstein Institutes, Manhasset

30322

Emory University, Atlanta

80045

University of Colorado, Aurora

85724

University of Arizona - Banner Health, Tucson

90095

University of California, Los Angeles, Los Angeles

92037

Scripps Health, La Jolla

University of California, San Diego, San Diego

92868

University of California, Irvine, Orange

94143

University of California, San Francisco, San Francisco

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

California Institute for Regenerative Medicine (CIRM)

OTHER

lead

Aspen Neuroscience

INDUSTRY